SE510305C2 - Nytt salt - Google Patents

Nytt salt

Info

Publication number
SE510305C2
SE510305C2 SE9702066A SE9702066A SE510305C2 SE 510305 C2 SE510305 C2 SE 510305C2 SE 9702066 A SE9702066 A SE 9702066A SE 9702066 A SE9702066 A SE 9702066A SE 510305 C2 SE510305 C2 SE 510305C2
Authority
SE
Sweden
Prior art keywords
salt
tartrate
benzopyran
dihydro
fluoro
Prior art date
Application number
SE9702066A
Other languages
English (en)
Swedish (sv)
Other versions
SE9702066L (sv
SE9702066D0 (sv
Inventor
Haakan Nykvist
Daniel Sohn
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Priority to SE9702066A priority Critical patent/SE510305C2/sv
Publication of SE9702066D0 publication Critical patent/SE9702066D0/xx
Priority to TW087107397A priority patent/TW510899B/zh
Priority to PCT/SE1998/000907 priority patent/WO1998054166A1/en
Priority to EEP199900549A priority patent/EE03874B1/xx
Priority to SI9830332T priority patent/SI0984952T1/xx
Priority to PT98925993T priority patent/PT984952E/pt
Priority to CA002291732A priority patent/CA2291732C/en
Priority to KR19997011107A priority patent/KR20010013127A/ko
Priority to CNB988056631A priority patent/CN1198814C/zh
Priority to BR9809519-6A priority patent/BR9809519A/pt
Priority to RU99128026/04A priority patent/RU2193560C2/ru
Priority to TR1999/02926T priority patent/TR199902926T2/xx
Priority to EP98925993A priority patent/EP0984952B1/en
Priority to US09/077,718 priority patent/US6858645B2/en
Priority to UA99127241A priority patent/UA53720C2/uk
Priority to ES98925993T priority patent/ES2187030T3/es
Priority to AU77923/98A priority patent/AU729301B2/en
Priority to IDW991407A priority patent/ID23794A/id
Priority to DK98925993T priority patent/DK0984952T3/da
Priority to PL98337181A priority patent/PL337181A1/xx
Priority to JP50056099A priority patent/JP3554338B2/ja
Priority to YU62499A priority patent/YU62499A/sh
Priority to AT98925993T priority patent/ATE228121T1/de
Priority to HU0001878A priority patent/HUP0001878A3/hu
Priority to DE69809547T priority patent/DE69809547T2/de
Priority to SK1594-99A priority patent/SK282755B6/sk
Priority to NZ501075A priority patent/NZ501075A/en
Priority to IL13323498A priority patent/IL133234A/en
Priority to ZA984486A priority patent/ZA984486B/xx
Priority to ARP980102434A priority patent/AR012751A1/es
Priority to MYPI98002400A priority patent/MY117960A/en
Publication of SE9702066L publication Critical patent/SE9702066L/xx
Publication of SE510305C2 publication Critical patent/SE510305C2/sv
Priority to IS5270A priority patent/IS1943B/is
Priority to NO995853A priority patent/NO995853L/no
Priority to BG103949A priority patent/BG64051B1/bg
Priority to HK00104934A priority patent/HK1025575A1/xx
Priority to US10/964,388 priority patent/US20050085532A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
SE9702066A 1997-05-30 1997-05-30 Nytt salt SE510305C2 (sv)

Priority Applications (36)

Application Number Priority Date Filing Date Title
SE9702066A SE510305C2 (sv) 1997-05-30 1997-05-30 Nytt salt
TW087107397A TW510899B (en) 1997-05-30 1998-05-13 A salt (R)-3-N,N-dicyclobutyamino-8-fluoro-3,4-dihydro-2H-1-benzopyran-5-carboxamide hydrogen (2R,3R)-tartrate, a pharmaceutical composition containing said salt and a process for the manufacture of said salt
IL13323498A IL133234A (en) 1997-05-30 1998-05-15 Hydrogen Tartrate of (R) - 3 (N, N-Dicyclobutyl-Amino) - 8 Fluoro-4,3 Dihydro 1 H2-Benzopyran-5-Carboxamide, process for its preparation and pharmaceutical preparations containing it
SI9830332T SI0984952T1 (en) 1997-05-30 1998-05-15 A new salt
JP50056099A JP3554338B2 (ja) 1997-05-30 1998-05-15 新規な塩
DK98925993T DK0984952T3 (da) 1997-05-30 1998-05-15 Hidtil ukendt salt
EEP199900549A EE03874B1 (et) 1997-05-30 1998-05-15 (R)-3-N,N-ditsüklobutüülamino-8-fluoro-3,4-dihüdro-2H-1-bensopüraan-5-karboksam iidvesinik- tartraat, selle valmistamise meetod ja seda sisaldav ravimkoostis
CA002291732A CA2291732C (en) 1997-05-30 1998-05-15 A salt (r)-3-n,n-dicyclobutylamino-8-fluoro-3,4-dihydro-2h-1-benzopyran-5-carboxaminde hydrogen (2r,3r)-tartrate
KR19997011107A KR20010013127A (ko) 1997-05-30 1998-05-15 신규 염
CNB988056631A CN1198814C (zh) 1997-05-30 1998-05-15 一种新的盐
BR9809519-6A BR9809519A (pt) 1997-05-30 1998-05-15 Sal, processo para fabricação e uso do mesmo, formulação farmacêutica, e, processo para prevenção ou tratamento de distúrbios cns e perturbações médicas relacionadas
RU99128026/04A RU2193560C2 (ru) 1997-05-30 1998-05-15 Новая соль
TR1999/02926T TR199902926T2 (xx) 1997-05-30 1998-05-15 Yeni bir tuz.
EP98925993A EP0984952B1 (en) 1997-05-30 1998-05-15 A new salt
US09/077,718 US6858645B2 (en) 1997-05-30 1998-05-15 Tartrate salts of (R) -3-N,N- dicyclobutylamino-8-fluoro-3,4-dihydro-2H-1- benzopyran-5-carboxamide
UA99127241A UA53720C2 (uk) 1997-05-30 1998-05-15 Кислий (2r,3r)-тартрат (r)-3-n,n-дициклоаміно-8-фтор-3,4-дигідро-2н-1-бензопіран-5-карбоксаміду, його моногідрат, спосіб їх одержання та фармацевтична композиція
ES98925993T ES2187030T3 (es) 1997-05-30 1998-05-15 Una nueva sal.
AU77923/98A AU729301B2 (en) 1997-05-30 1998-05-15 A new salt
IDW991407A ID23794A (id) 1997-05-30 1998-05-15 Proses, pembuatan dan penggunaan garam bentuk (2r, 3r) tartrat
PCT/SE1998/000907 WO1998054166A1 (en) 1997-05-30 1998-05-15 A new salt
PT98925993T PT984952E (pt) 1997-05-30 1998-05-15 Novo sal
PL98337181A PL337181A1 (en) 1997-05-30 1998-05-15 Novel salt
YU62499A YU62499A (sh) 1997-05-30 1998-05-15 Nova so
AT98925993T ATE228121T1 (de) 1997-05-30 1998-05-15 Neues salz
HU0001878A HUP0001878A3 (en) 1997-05-30 1998-05-15 (r)-3-(n,n-dicyclobutyl-amino)-8-fluoro-3,4-dihydro-2h-1-benzopyran-5-carboxamide hydrogen tartrate, process for its preparation and pharmatceutical compositions of the same
DE69809547T DE69809547T2 (de) 1997-05-30 1998-05-15 Neues salz
SK1594-99A SK282755B6 (sk) 1997-05-30 1998-05-15 Soľ karboxamidhydrogenvínan, spôsob jej prípravy, farmaceutický prípravok s jej obsahom a jej použitie
NZ501075A NZ501075A (en) 1997-05-30 1998-05-15 (R)-3-N,N-dicyclobutylamino-8-fluoro-3,4-dihydro-2H-1-benzopyran-5-carboxamide hydrogen (2R,3R)-tartrate
ARP980102434A AR012751A1 (es) 1997-05-30 1998-05-26 Sales de hidrogeno tartrato de (r) -3-n,n-diciclobutilamino-8-fluoro-3,4 -dihidro-2h-1-benzopiran-5-carboxamida, su uso para la fabricacion de medicamentos para tratar trastornos de snc y trastornos medicos relacionados y procedimiento para la fabricacion de dichas sales
ZA984486A ZA984486B (en) 1997-05-30 1998-05-26 A new salt
MYPI98002400A MY117960A (en) 1997-05-30 1998-05-29 A new salt
IS5270A IS1943B (is) 1997-05-30 1999-11-24 (R)-3-N,N-dísýklóbútýlamínó-8-flúor-3,4-díhýdró-2H-1-bensópýran-5-karboxamíðhýdrógentartrat, aðferðvið framleiðslu þess og lyfjablöndur sem innihalda það
NO995853A NO995853L (no) 1997-05-30 1999-11-29 Nytt salt
BG103949A BG64051B1 (bg) 1997-05-30 1999-12-03 Нова сол
HK00104934A HK1025575A1 (en) 1997-05-30 2000-08-08 A new salt
US10/964,388 US20050085532A1 (en) 1997-05-30 2004-10-12 Tartrate salts of (R)-3-N,N-dicyclo-butylamino-8-fluoro-3,4-dihydro-2H-1-benzopyran-5-carboxamide

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9702066A SE510305C2 (sv) 1997-05-30 1997-05-30 Nytt salt

Publications (3)

Publication Number Publication Date
SE9702066D0 SE9702066D0 (sv) 1997-05-30
SE9702066L SE9702066L (sv) 1998-12-01
SE510305C2 true SE510305C2 (sv) 1999-05-10

Family

ID=20407187

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9702066A SE510305C2 (sv) 1997-05-30 1997-05-30 Nytt salt

Country Status (34)

Country Link
US (2) US6858645B2 (zh)
EP (1) EP0984952B1 (zh)
JP (1) JP3554338B2 (zh)
KR (1) KR20010013127A (zh)
CN (1) CN1198814C (zh)
AR (1) AR012751A1 (zh)
AT (1) ATE228121T1 (zh)
AU (1) AU729301B2 (zh)
BG (1) BG64051B1 (zh)
BR (1) BR9809519A (zh)
CA (1) CA2291732C (zh)
DE (1) DE69809547T2 (zh)
DK (1) DK0984952T3 (zh)
EE (1) EE03874B1 (zh)
ES (1) ES2187030T3 (zh)
HK (1) HK1025575A1 (zh)
HU (1) HUP0001878A3 (zh)
ID (1) ID23794A (zh)
IL (1) IL133234A (zh)
IS (1) IS1943B (zh)
MY (1) MY117960A (zh)
NO (1) NO995853L (zh)
NZ (1) NZ501075A (zh)
PL (1) PL337181A1 (zh)
PT (1) PT984952E (zh)
RU (1) RU2193560C2 (zh)
SE (1) SE510305C2 (zh)
SK (1) SK282755B6 (zh)
TR (1) TR199902926T2 (zh)
TW (1) TW510899B (zh)
UA (1) UA53720C2 (zh)
WO (1) WO1998054166A1 (zh)
YU (1) YU62499A (zh)
ZA (1) ZA984486B (zh)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102888D0 (sv) * 2001-08-29 2001-08-29 Astrazeneca Ab New formulation
SE0102887D0 (sv) * 2001-08-29 2001-08-29 Astrazeneca Ab New formulation
SE0102886D0 (sv) * 2001-08-29 2001-08-29 Astrazeneca Ab New formulation
SE0301795D0 (sv) * 2003-06-19 2003-06-19 Astrazeneca Ab New use I
SE0301796D0 (sv) * 2003-06-19 2003-06-19 Astrazeneca Ab New use II
ATE528807T1 (de) * 2006-05-11 2011-10-15 Johnson Controls Saft Advanced Power Solutions Llc Modulares batteriesystem
JP5163931B2 (ja) * 2007-03-08 2013-03-13 株式会社リコー 定着装置及び画像形成装置
EP2065385A1 (en) * 2007-11-28 2009-06-03 Laboratorios SALVAT, S.A. Stable crystalline salt of (R)-3-fluorophenyl-3,4,5-trifluorobenzylcarbamic acid 1-azabiciyclo [2.2.2]oct-3-yl ester
CN103788043B (zh) * 2008-11-28 2016-02-03 中国医学科学院药物研究所 硝克柳胺化合物晶iv型、其制法和其药物组合物与用途
CA2910085C (en) * 2013-04-26 2021-05-25 Sanofi Tartrate salt of 5-chloro-thiophene-2-carboxylic acid [(s)-2-[methyl-3-(2-oxo-pyrrolidin-1-yl)-benzenesulfonylamino]-3-(4-methyl-piperazin-1-yl)-3-oxo-propryl]amide

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5616610A (en) 1989-12-22 1997-04-01 Astra Aktiebolag (R)-5-carbamoyl-8-fluoro-3-N,N-disubstituted-amino-3,4-dihydro-2H-1-benzopyrans
US5420151A (en) 1989-12-22 1995-05-30 Aktiebolaget Astra Chroman derivatives
IT1282705B1 (it) 1996-02-28 1998-03-31 Recordati Chem Pharm Uso di antagonisti del recettore serotoninergico 5-ht|a per il trattamento dell'incontinenza urinaria
US5990114A (en) 1996-02-28 1999-11-23 Recordati, S.A., Chemical And Pharmaceutical Company Use of 5-HT1A receptor antagonists for the treatment of urinary incontinence

Also Published As

Publication number Publication date
JP2002501527A (ja) 2002-01-15
DE69809547D1 (de) 2003-01-02
EE9900549A (et) 2000-06-15
EP0984952B1 (en) 2002-11-20
CA2291732C (en) 2003-12-30
US20030109576A1 (en) 2003-06-12
ES2187030T3 (es) 2003-05-16
DE69809547T2 (de) 2003-08-21
HK1025575A1 (en) 2000-11-17
CA2291732A1 (en) 1998-12-03
KR20010013127A (ko) 2001-02-26
SK159499A3 (en) 2000-10-09
ATE228121T1 (de) 2002-12-15
AU729301B2 (en) 2001-02-01
HUP0001878A2 (hu) 2001-05-28
NO995853D0 (no) 1999-11-29
BG64051B1 (bg) 2003-11-28
AU7792398A (en) 1998-12-30
EP0984952A1 (en) 2000-03-15
SE9702066L (sv) 1998-12-01
US6858645B2 (en) 2005-02-22
IS5270A (is) 1999-11-24
DK0984952T3 (da) 2003-02-24
TR199902926T2 (xx) 2000-03-21
BG103949A (en) 2000-07-31
SK282755B6 (sk) 2002-12-03
AR012751A1 (es) 2000-11-08
WO1998054166A1 (en) 1998-12-03
IS1943B (is) 2004-08-13
NZ501075A (en) 2001-08-31
MY117960A (en) 2004-08-30
PL337181A1 (en) 2000-08-14
TW510899B (en) 2002-11-21
YU62499A (sh) 2002-06-19
US20050085532A1 (en) 2005-04-21
NO995853L (no) 2000-01-31
ID23794A (id) 2000-05-11
ZA984486B (en) 1998-11-30
EE03874B1 (et) 2002-10-15
UA53720C2 (uk) 2003-02-17
SE9702066D0 (sv) 1997-05-30
RU2193560C2 (ru) 2002-11-27
CN1258290A (zh) 2000-06-28
IL133234A0 (en) 2001-03-19
HUP0001878A3 (en) 2002-04-29
PT984952E (pt) 2003-03-31
CN1198814C (zh) 2005-04-27
BR9809519A (pt) 2000-06-20
IL133234A (en) 2004-05-12
JP3554338B2 (ja) 2004-08-18

Similar Documents

Publication Publication Date Title
US10844058B2 (en) Valbenazine salts and polymorphs thereof
EP1818329B1 (en) (s)-(-)-1-(4-fluoroisoquinolin-5-yl)sulfonyl-2methyl-1,4homopiperazine hydrochloride dihydrate
EP1440969A1 (en) Alpha-form or beta-form crystal of acetanilide derivative
NO341013B1 (no) Fremgangsmåte for fremstilling av atazanavirbisulfat,og former derav
EP3022209B1 (en) Dolutegravir potassium salt
SE510305C2 (sv) Nytt salt
KR101319516B1 (ko) 퓨린 유도체
KR101710740B1 (ko) 2-［［［2-［(히드록시아세틸)아미노］-4-피리디닐］메틸］티오］-ｎ-［4-(트리플루오로메톡시)페닐］-3-피리딘카르복사미드의 벤젠술폰산염, 이의 결정, 이의 결정 다형 및 이들의 제조 방법
KR20240000540A (ko) (s)-n-(3-(2-(((r)-1-하이드록시프로판-2-일)아미노)-6-모르폴리노피리딘-4-일)-4-메틸페닐)-3-(2,2,2-트리플루오로에틸)피롤리딘-1-카르복스아미드 및 이의 염의 고체 상태 형태
KR101557832B1 (ko) (ｒ)-3-플루오로페닐-3,4,5-트리플루오로벤질카르밤산 1-아자비시클로 [2.2.2]옥트-3-일 에스테르의 안정한 결정성 염
KR101653816B1 (ko) 결정형 사포그릴레이트 옥살산염 일수화물 또는 이의 무수물
KR100372964B1 (ko) 피페리딘유도체결정,이의제조용중간생성물및이의제조방법
KR101423630B1 (ko) 비칼루타미드와 니코틴아미드의 공결정
WO2020042903A1 (zh) 一种环己烷衍生物的盐
US10870627B2 (en) Salt of quinazoline derivative, preparation method therefor and application thereof
CZ426199A3 (cs) Nová sůl
MXPA99010942A (en) A new salt
TW202216726A (zh) 八氫噻吩并喹啉化合物之琥珀酸鹽及其結晶
CN112851641A (zh) 嘧啶苯甲酰胺化合物的盐酸盐及其用途

Legal Events

Date Code Title Description
NUG Patent has lapsed